Answers are grounded in this paper and cite their sources.
To highlight oversimplified quality-adjusted life year (QALY) calculations and incremental cost-effectiveness ratios (ICERs) regarding lifestyle metformin and placebo as flaws in the trial-based (Diabetes Prevention Program) cost-effectiveness analysis.
No takes yet. Share an insight, caveat, or question.
Rittenhouse et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: